natgillin/translations-raw huggingface dataset:
In healthy volunteers receiving sildenafil (100 mg single dose), less than 0.0002% (average 188 ng) of the administered dose was present in ejaculate 90 minutes after dosing.
U zdravih dobrovoljaca koji su primali sildenafil (100 mg u jednokratnoj dozi), manje od 0,0002% (prosječno 188 ng) primijenjene doze prisutno je u ejakulatu 90 minuta nakon doziranja.
The postulated mechanism for this change in colour discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina.
Pretpostavljeni mehanizam za ovu promjenu u raspoznavanju boje povezan je s inhibicijom PDE6, koja je uključena u fototransdukcijsku kaskadu mrežnice.
From post-marketing experience cases of unstable angina (a heart condition) and sudden death have been reported rarely.
Nakon stavljanja lijeka u promet prijavljeni su rijetki slučajevi nestabilne angine (srčani poremećaj) i iznenadne smrti.
When sildenafil and doxazosin were administered simultaneously to patients stabilized on doxazosin therapy, there were infrequent reports of patients who experienced symptomatic postural hypotension.
Kada su sildenafil i doksazosin istodobno primjenjivani bolesnicima stabiliziranima na terapiji doksazosinom, bilo je povremenih izvještaja o bolesnicima koji su imali simptomatsku posturalnu hipotenziju.
Sildenafil has a peripheral site of action on erections.
Sildenafil ima periferno mjesto djelovanja na erekcije.
- An allergic reaction - this occurs uncommonly (may affect up to 1 in 100 people).
Alergijska reakcija - javlja se manje često (može se javiti u najviše 1 na 100 osoba).
Sildenafil (50 mg) did not potentiate the hypotensive effects of alcohol in healthy volunteers with mean maximum blood alcohol levels of 80 mg/dl.
Sildenafil (50 mg) nije potencirao hipotenzivne učinke alkohola u zdravih dobrovoljaca sa srednjim maksimalnim razinama alkohola u krvi od 80 mg/dl.
If sildenafil is taken with food, the onset of activity may be delayed compared to the fasted state (see section 5.2).
Ako se sildenafil uzima s hranom, nastup djelovanja može biti odgođen u usporedbi s uzimanjem natašte (vidjeti dio 5.2).
If you experience any of the following serious side effects stop taking Sildenafil ratiopharm and seek medical help immediately:
Ako primijetite bilo koju od sljedećih ozbiljnih nuspojava, prestanite uzimati Sildenafil ratiopharm i odmah zatražite medicinsku pomoć:
When sildenafil is taken with food, the rate of absorption is reduced with a mean delay in tmax of 60 minutes and a mean reduction in Cmax of 29%.
Prilikom uzimanja sildenafila s hranom, brzina apsorpcije je smanjena sa srednjom odgodom tmax od 60 minuta i srednjim smanjenjem Cmax od 29%.
What you need to know before you take Sildenafil ratiopharm
Što morate znati prije nego počnete uzimati Sildenafil ratiopharm
Given sildenafil peak plasma concentrations of approximately 1 µM after recommended doses, it is unlikely that sildenafil will alter the clearance of substrates of these isoenzymes.
S obzirom da su nakon preporučenih doza vršne koncentracije sildenafila u plazmi približno 1 µM, nije vjerojatno da će sildenafil promijeniti klirens supstrata tih izoenzima.
The following groups were not well represented or excluded from clinical trials: patients with pelvic surgery, patients post-radiotherapy, patients with severe renal or hepatic impairment and patients with certain cardiovascular conditions (see section 4.3).
Sljedeće skupine nisu dobro zastupljene ili su isključene iz kliničkih ispitivanja: bolesnici s operacijom u području zdjelice, bolesnici nakon radioterapije, bolesnici s teškim poremećajem funkcije bubrega ili jetre i bolesnici s određenim kardiovaskularnim stanjima (vidjeti dio 4.3).
In a penile plethysmography (RigiScan) study of fasted patients, the median time to onset for those who obtained erections of 60% rigidity (sufficient for sexual intercourse) was 25 minutes (range 12-37 minutes) on sildenafil.
Ispitivanjem pomoću penilne pletizmografije (RigiScan) u bolesnika natašte, medijan vremena do pojave za one koji su postigli erekcije od 60% rigiditeta (dovoljno za spolni odnos) iznosila je 25 minuta (raspon 12-37 minuta) za sildenafil.
Since sildenafil (and its major circulating N-desmethyl metabolite) is 96% bound to plasma proteins, this results in the mean maximum free plasma concentration for sildenafil of 18 ng/mL (38 nM).
Budući da je sildenafil (i njegov glavni cirkulirajući N-dezmetil metabolit) 96% vezan na proteine u plazmi, to rezultira srednjom maksimalnom koncentracijom slobodnog sildenafila u plazmi od 18 ng/ml (38 nM).
The major circulating metabolite results from N-demethylation of sildenafil.
Glavni cirkulirajući metabolit nastaje N-demetilacijom sildenafila.
Sildenafil has vasodilator properties, resulting in mild and transient decreases in blood pressure (see section 5.1).
Sildenafil ima vazodilatatorna svojstva, što rezultira blagim i prolaznim sniženjem krvnog tlaka (vidjeti dio 5.1).
There was no evidence of favourable clinical effect of the combination in the population studied.
U ispitivanoj populaciji nije dokazan povoljan klinički učinak kombinirane terapije.
This is most likely to occur within 4 hours post sildenafil dosing (see sections 4.2 and 4.4).
Do toga će najvjerojatnije doći unutar 4 sata nakon primjene doze sildenafila (vidjeti dijelove 4.2 i 4.4).
Sildenafil had no effect on saquinavir pharmacokinetics (see section 4.2).
Sildenafil nije imao učinka na farmakokinetiku sakvinavira (vidjeti dio 4.2).
In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC, Cmax, tmax, elimination rate constant, or subsequent half-life of sildenafil or its principal circulating metabolite.
U normalnih, zdravih muških dobrovoljaca, nije bilo dokaza o utjecaju azitromicina (500 mg dnevno tijekom 3 dana) na AUC, Cmax, tmax, konstantu brzine eliminacije ili poluvrijeme sildenafila ili njegovog glavnog cirkulirajućeg metabolita.
There is no safety information on the administration of sildenafil to patients with bleeding disorders or active peptic ulceration.
Nema informacija o sigurnosti primjene sildenafila u bolesnika s poremećajima krvarenja ili aktivnim peptičnim ulkusom.
Studies in vitro have shown that sildenafil is selective for PDE5, which is involved in the erection process.
In vitro ispitivanja pokazala su da je sildenafil selektivan za PDE5, koja je uključena u proces erekcije.
At 24 hours, the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was administered alone.
U 24 sata, razine sildenafila u plazmi bile su još uvijek približno 200 ng/ml, u usporedbi s približno 5 ng/ml kada se sildenafil davao zasebno.
Therefore, concomitant administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in plasma concentrations of sildenafil.
Zbog toga se kod istodobne primjene jakih CYP3A4 induktora, kao što je rifampin, očekuju veća smanjenja koncentracije sildenafila u plazmi.
Adverse reactions from post-marketing surveillance has been gathered covering an estimated period > 10 years.
Nuspojave nakon stavljanja lijeka u promet prikupljene su u razdoblju procijenjenom na >10 godina.
Doses of 200 mg did not result in increased efficacy but the incidence of adverse reactions (headache, flushing, dizziness, dyspepsia, nasal congestion, altered vision) was increased.
Doze od 200 mg nisu rezultirale povećanom djelotvornošću, već je porasla incidencija nuspojava (glavobolja, naleti crvenila, omaglica, dispepsija, nazalna kongestija, promjenjen vid).
Sildenafil is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).
Sildenafil je kontraindiciran u bolesnika koji su izgubili vid na jednom oku zbog nearteritične anteriorne ishemijske optičke neuropatije (NAION), bez obzira je li ta epizoda bila u vezi ili ne s prethodnom izloženošću PDE5 inhibitoru (vidjeti dio 4.4).
- Serious skin reactions - this occurs rarely.
Ozbiljne kožne reakcije - javljaju se rijetko.
Riociguat: Preclinical studies showed additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat.
Riociguat: Pretklinička ispitivanja pokazala su aditivan učinak na snižavanje krvnog tlaka kada su se inhibitori PDE5 primjenjivali u kombinaciji sa riociguatom.
Do NOT take Sildenafil ratiopharm: - if you are allergic to sildenafil or any of the other ingredients of this medicine (listed in section
NEMOJTE uzimati Sildenafil ratiopharm - ako ste alergični na sildenafil ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
How to store Sildenafil ratiopharm Contents of the pack and other information
Kako čuvati Sildenafil ratiopharm Sadržaj pakiranja i druge informacije
The following patient groups were represented: elderly (19.9%), patients with hypertension (30.9%), diabetes mellitus (20.3%), ischaemic heart disease (5.8%), hyperlipidaemia (19.8%), spinal cord injury (0.6%), depression (5.2%), transurethral resection of the prostate (3.7%), radical prostatectomy (3.3%).
Zastupljene su sljedeće skupine bolesnika: stariji (19,9%), bolesnici s hipertenzijom (30,9%), dijabetes melitusom (20,3%), ishemijskom bolesti srca (5,8%), hiperlipidemijom (19,8%), ozljedom leđne moždine (0,6%), depresijom (5,2%), transuretralnom resekcijom prostate (3,7%), radikalnom prostatektomijom (3,3%).
ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Germany
ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Njemačka
Due to age-differences in plasma protein binding, the corresponding increase in free sildenafil plasma concentration was approximately
Zbog dobnih razlika u vezanju na proteine plazme, odgovarajući porast koncentracija slobodnog sildenafila u plazmi iznosio je približno 40%.
Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP.
Sildenafil je jak i selektivan inhibitor cGMP specifične fosfodiesteraze tipa 5 (PDE5) u korpus kavernozumu, gdje je PDE5 odgovorna za razgradnju cGMP.
In fixed dose studies, the proportions of patients reporting that treatment improved their erections were 62% (25 mg), 74% (50 mg) and 82% (100 mg) compared to 25% on placebo.
U ispitivanjima s fiksnom dozom, udjeli bolesnika koji su prijavili da im je liječenje poboljšalo erekciju iznosili su 62% (25 mg), 74% (50 mg) i 82% (100 mg) u usporedbi s 25% kod placeba.
In a medical emergency, you must tell anyone treating you that you have taken Sildenafil ratiopharm.
U hitnim slučajevima, liječniku morate reći da ste uzeli Sildenafil ratiopharm.
Sudden cardiac death*, Myocardial infarction, Ventricular arrhythmia*, Atrial fibrillation, Unstable angina
Iznenadna srčana smrt,* infarkt miokarda, ventrikularna aritmija,* fibrilacija atrija, nestabilna angina
Based on these pharmacokinetic results co-administration of sildenafil with ritonavir is not advised (see section 4.4) and in any event the maximum dose of sildenafil should under no circumstances exceed 25 mg within 48 hours.
S obzirom na te farmakokinetičke rezultate, istodobna primjena sildenafila s ritonavirom se ne preporučuje (vidjeti dio 4.4) te ni u kom slučaju maksimalna doza sildenafila ne smije premašiti 25 mg unutar 48 sati.
Somnolence, Hypoaesthesia
Somnolencija, hipoestezija
The dosing recommendations described in ‘Use in adults' apply to patients with mild to moderate renal impairment (creatinine clearance = 30-80 mL/min).
Preporuke za doziranje opisane pod „Primjena u odraslih osoba“ odnose se na bolesnike s blagim do umjerenim oštećenjem funkcije bubrega (klirens kreatinina = 30-80 ml/min).
When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP.
Kada je NO/cGMP put aktiviran, što se događa uz seksualnu stimulaciju, inhibicija PDE5 sildenafilom rezultira povećanim vrijednostima cGMP u korpus kavernozumu.
Prior to prescribing sildenafil, physicians should carefully consider whether their patients with certain underlying conditions could be adversely affected by such vasodilatory effects, especially in combination with sexual activity.
Prije propisivanja sildenafila, liječnici moraju brižljivo razmotriti mogu li takvi vazodilatatorni učinci štetno utjecati na njihove bolesnike s određenim primarnim bolestima, osobito u kombinaciji sa spolnom aktivnošću.
Agents for the treatment of erectile dysfunction, including sildenafil, should not be used in men for whom sexual activity is inadvisable (e.g. patients with severe cardiovascular disorders such as unstable angina or severe cardiac failure).
Sredstva za liječenje erektilne disfunkcije, uključujući sildenafil, ne smiju koristiti muškarci kojima se spolna aktivnost ne preporučuje (npr. bolesnici s teškim kardiovaskularnim poremećajima kao što su nestabilna angina ili teško zatajenje srca).
Sildenafil ratiopharm contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Sildenafil ratiopharm sadrži djelatnu tvar sildenafil koja pripada skupini lijekova pod nazivom inhibitori fosfodiesteraze tipa 5 (PDE5).
PDE5 inhibitors, such as sildenafil, have been shown to increase the hypotensive effects of this medicine.
Inhibitori PDE5, kao što je sildenafil, pokazali su da povećavaju hipotenzivne učinke ovog lijeka.
Studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside in vitro.
Ispitivanja s ljudskim trombocitima pokazuju da sildenafil pojačava antiagregacijski učinak natrijevog nitroprusida in vitro.
Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance.
Zbog toga inhibitori tih izoenzima mogu smanjiti klirens sildenafila, a induktori ovih izoenzima mogu povećati klirens sildenafila.
Healthy, elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 90% higher plasma concentrations of sildenafil and the active N-desmethyl metabolite compared to those seen in healthy younger volunteers (18-45 years).
Zdravi stariji dobrovoljci (65 godina ili stariji) imali su smanjeni klirens sildenafila, što je rezultiralo približno 90% višim koncentracijama sildenafila i aktivnog N-dezmetil metabolita u plazmi u usporedbi s koncentracijama opaženim u zdravih mlađih dobrovoljaca (18-45 godina).
Symptoms may include severe peeling and swelling of the skin, blistering of the mouth, genitals and around the eyes, fever.
Simptomi mogu uključivati jako ljuštenje i oticanje kože, plikove u ustima, na genitalijama i oko očiju, vrućicu.
Population pharmacokinetic analysis of clinical trial data indicated a reduction in sildenafil clearance when co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, cimetidine).
Populacijska farmakokinetička analiza podataka iz kliničkog ispitivanja pokazuje smanjenje klirensa sildenafila kada se primjenjuje istodobno s CYP3A4 inhibitorima (kao što su ketokonazol, eritromicin, cimetidin).
Sildenafil (50 mg) did not potentiate the increase in bleeding time caused by acetyl salicylic acid (150 mg).
Sildenafil (50 mg) nije potencirao produljenje vremena krvarenja, izazvano acetilsalicilnom kiselinom (150 mg).
These decreases in blood pressure are consistent with the vasodilatory effects of sildenafil, probably due to increased cGMP levels in vascular smooth muscle.
Ova sniženja krvnog tlaka su u skladu s vazodilatatornim učincima sildenafila, vjerojatno zbog povišenih vrijednosti cGMP u glatkim mišićima krvnih žila.
In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased by 200% and 79% respectively.
Nadalje, vrijednosti AUC i Cmax N-dezmetil metabolita bile su značajno povećane, 200% odnosno 79%.
Chest pain, Fatigue, Feeling hot
Bol u prsima, umor, osjećaj vrućine
This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% that of the parent drug.
Ovaj metabolit ima profil selektivnosti za fosfodiesterazu koji je sličan sildenafilu te in vitro djelovanje na PDE5 koje iznosi približno 50% od onog za ishodišni lijek.
There is a 10-fold selectivity over PDE6 which is involved in the phototransduction pathway in the retina.
Prisutna je 10 puta veća selektivnost u usporedbi s PDE6 koja je uključena u fototransdukcijski put u mrežnici.
Based on efficacy and tolerability, the dose may be increased to 100 mg or decreased to 25 mg.
S obzirom na djelotvornost i podnošljivost, doza se može povisiti do 100 mg ili sniziti do 25 mg.
This medicine is used to treat pulmonary arterial hypertension (i.e. high blood pressure in the lungs) and chronic thromboembolic pulmonary hypertension (i.e. high blood pressure in the lungs secondary to blood clots).
Ovaj lijek se primjenjuje u liječenju plućne arterijske hipertenzije (kod visokog krvnog tlaka u plućima) i kronične tromboembolijske plućne hipertenzije (kod visokog krvnog tlaka u plućima kao posljedica stvaranja krvnih ugrušaka).
This medicine allows an erection to last long enough for you to satisfactorily complete sexual activity.
Ovaj lijek osigurava dovoljno dugo trajanje erekcije za zadovoljavajući spolni odnos.
Nausea, Dyspepsia
Mučnina, dispepsija
The side effects reported in association with the use of sildenafil are usually mild to moderate and of a short duration.
Nuspojave zabilježene kod primjene sildenafila obično su blage do umjerene i kratko traju.
Sildenafil ratiopharm will only work when you are sexually stimulated.
Sildenafil ratiopharm djeluje samo uz seksualnu stimulaciju.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti, nuspojave su prikazane prema ozbiljnosti, silaznim redoslijedom.
These additional blood pressure reductions were of a similar magnitude to those seen when sildenafil was administered alone to healthy volunteers (see section 5.1).
Ova dodatna sniženja krvnog tlaka bila su po jačini slična onima koja su uočena kod zasebne primjene sildenafila zdravim dobrovoljcima (vidjeti dio 5.1).
The safety of sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated: severe hepatic impairment, hypotension (blood pressure < 90/50 mmHg), recent history of stroke or myocardial infarction and known hereditary degenerative retinal disorders such as retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases).
Sigurnost sildenafila nije ispitana u sljedećim podskupinama bolesnika te je njegova primjena stoga kontraindicirana: teško oštećenje jetre, hipotenzija (krvni tlak <90/50 mm Hg), anamneza nedavnog moždanog udara ili infarkta miokarda i poznati nasljedni degenerativni poremećaji retine kao što su retinitis pigmentosa (manji dio tih bolesnika ima genetske poremećaje retinalnih fosfodiesteraza).
Hypertension, Hypotension
Hipertenzija, hipotenzija
Sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates.
Sildenafil (100 mg) nije utjecao na farmakokinetiku stanja dinamičke ravnoteže inhibitora HIV proteaze, sakvinavira i ritonavira, koji su CYP3A4 supstrati.
Take ½ or 1 film-coated tablet of Sildenafil ratiopharm as prescribed by your doctor about 1 hour before sexual activity.
Uzmite ½ ili 1 filmom obloženu tabletu lijeka Sildenafil ratiopharm, prema uputama Vašeg liječnika, oko sat vremena prije spolnog odnosa.
No significant interactions were shown when sildenafil (50 mg) was co-administered with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolised by CYP2C9.
Nisu zabilježene značajne interakcije kod istodobne primjene sildenafila (50 mg) s tolbutamidom (250 mg) ili varfarinom (40 mg), lijekovima koji se metaboliziraju putem CYP2C9.
There was no effect on sperm motility or morphology after single 100 mg oral doses of sildenafil in healthy volunteers (see section 5.1).
Nije bilo učinka na motilitet ili morfologiju spermija nakon jednokratnih peroralnih doza od 100 mg sildenafila kod zdravih dobrovoljaca (vidjeti dio 5.1).
What Sildenafil ratiopharm contains - The active substance is sildenafil.
Što Sildenafil ratiopharm sadrži - Djelatna tvar je sildenafil.
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy.
U tri specifična ispitivanja interakcije lijek-lijek, alfa-blokator doksazosin (4 mg i 8 mg) i sildenafil (25 mg, 50 mg ili 100 mg) primijenjeni su istodobno u bolesnika s benignom hiperplazijom prostate (BHP) stabiliziranima na terapiji doksazosinom.
In a specific interaction study, where sildenafil (100 mg) was co-administered with amlodipine in hypertensive patients, there was an additional reduction on supine systolic blood pressure of 8 mmHg.
U specifičnom ispitivanju interakcije, gdje se sildenafil (100 mg) primjenjivao istodobno s amlodipinom u bolesnika s hipertenzijom, došlo je do dodatnog sniženja sistoličkog krvnog tlaka u ležećem položaju od 8 mmHg.
The mean maximum decreases in supine systolic blood pressure following 100 mg oral dosing of sildenafil was 8.4 mmHg.
Srednje maksimalno sniženje sistoličkog krvnog tlaka u ležećem položaju nakon oralnog doziranja sildenafila od 100 mg iznosilo je 8,4 mmHg.
In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in the visual tests conducted (visual acuity, Amsler grid, colour discrimination simulated traffic light, Humphrey perimeter and photostress).
U malom placebom kontroliranom ispitivanju bolesnika s dokumentiranom ranom makularnom degeneracijom povezanom s dobi (n=9), sildenafil (jednokratna doza, 100 mg) nije prikazao značajne promjene u provedenim testovima vida (oštrina vida, Amslerova mreža, raspoznavanje boja simulacijom semafora, Humphreyev perimetar i fotostres).
In these study populations, mean additional reductions of supine blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, and mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were observed.
U ispitivanoj populaciji uočena su dodatna sniženja krvnog tlaka u ležećem položaju srednjih vrijednosti od 7/7 mmHg, 9/5 mmHg odnosno 8/4 mmHg te dodatna sniženja krvnog tlaka u stojećem položaju srednjih vrijednosti od 6/6 mmHg, 11/4 mmHg odnosno 4/5 mmHg.
Although specific interaction studies were not conducted for all medicinal products, population pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates).
Iako specifična ispitivanja interakcija nisu provedena za sve lijekove, populacijska farmakokinetička analiza nije ukazala na djelovanje istodobno primijenjenih terapija na farmakokinetiku sildenafila, grupiranih kao CYP2C9 inhibitori (kao što su tolbutamid, varfarin, fenitoin), CYP2D6 inhibitori (kao što su selektivni inhibitori ponovne pohrane serotonina, triciklični antidepresivi), tiazid i srodni diuretici, diuretici Henleove petlje i oni koji štede kalij, inhibitori angiotenzin konvertirajućeg enzima, blokatori kalcijevih kanala, antagonisti beta-adrenoreceptora ili induktori CYP450 metabolizma (kao što su rifampicin, barbiturati).